Eli Lilly vs Fresenius Kabi: A Continued Balancing Act for Doctrine of Equivalence?
Brian Coggio, Attorney, Fish & Richardson (USA)
Adrian Chew, Senior Associate, Bristows LLP (UK)
Daan De Laange, Partner, Brinkhof (NED)
Ewan Nettleton, Principal IP Counsel, Oncology Litigation, Novartis Pharma AG
Daniel Lim
Strategic Consideration for Patent Portfolio Litigation
Mark van Gardingen, Partner, Brinkhof
Kristin Cooklin, Head of Intellectual Property, Zentiva
Dr Inga- Marlene Pietsch, Principal Associate, Gowling WLG (GBR)
Discovering New Frontier for Second Medical Use Patent
Nitika Gupta Fiorella, Principal, Fish & Richardson (USA)
Tjibbe Douma, Partner, Bird & Bird (NED)
Tessa M. Malamud-Cohen, Director, Patents, Global Intellectual Property, Ferring Pharmaceuticals
Ewan Nettleton, Principal IP Counsel, Oncology Litigation, Novartis Pharma AG
Establishing a Successful Cross Border Relief Strategy
Cecile Teles, Head of Patent Attorney, Zentiva
Ricardo Dijkstra, Partner, Vondst (NED)
Divisional Patents Strategy: Safeguarding Innovation or Anti Competitive?
Rieke Kaup, DG Competition, European Commission
Sara Burghart, Lead IP Litigation Counsel – Global Litigation & Launch, Sandoz
Corinna Sundermann, Senior Vice President Intellectual Property, Fresenius Kabi Deutschland
Moderator: Stephan Neuhaus, Partner, Allen & Overy (DEU)
Dana Lucas
Dana is the Director of Partnerships and Product at the Good Face Project, the industry’s fastest growing AI-powered ingredient transparency and innovation platform for Cosmetics and Personal Care. Dana specializes in translating demonstrated problems into products through human centered design, and by leveraging her background in business development, marketing, and applied design. Dana holds a BS in Marketing from Tulane University and an MPS in Design Management & Communications from Georgetown University.
